RT Journal Article SR Electronic T1 Analytical Solution of a New SEIR Model Based on Latent Period-Infectious Period Chronological Order JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.12.14.21267812 DO 10.1101/2021.12.14.21267812 A1 Liu, Xiaoping YR 2021 UL http://medrxiv.org/content/early/2021/12/16/2021.12.14.21267812.abstract AB The Susceptible-Infectious-Recovered (SIR) and SIR derived epidemic models have been commonly used to analyze the spread of infectious diseases. The underlying assumption in these models, such as Susceptible-Exposed-Infectious-Recovered (SEIR) model, is that the change in variables E, I or R at time t is dependent on a fraction of E and I at time t. This means that after exposed on a day, this individual may become contagious or even recover on the same day. However, the real situation is different: an exposed individual will become infectious after a latent period (l) and then recover after an infectious period (i). In this study, we proposed a new SEIR model based on the latent period-infectious period chronological order (Liu X., Results Phys. 2021; 20:103712). An analytical solution to equations of this new SEIR model was derived. From this new SEIR model, we obtained a propagated curve of infectious cases under conditions l>i. Similar propagated epidemic curves were reported in literature. However, the conventional SEIR model failed to simulate the propagated epidemic curves under the same conditions. For l<i, the new SEIR models generated bell-shaped curves for infectious cases, and the curve is near symmetrical to the vertical line passing the curve peak. This characteristic can be found in many epidemic curves of daily COVID-19 cases reported from different countries. However, the curve generated from the conventional SEIR model is a right-skewed bell-shaped curve. An example for applying the analytical solution of the new SEIR model equations to simulate the reported daily COVID-19 cases was also given in this paper.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors